drugset / Trial / NCT06108232
Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
To learn if obinutuzumab in combination with CC-99282 can help to control previously untreated, high tumor burden FL
Timeline
- Start
- 2024-03-15
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Golcadomide | Other / unclassified | — | Oral |
| Subject | Obinutuzumab | Monoclonal antibody | — | Intravenous |